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Abstract
In recent years, the world has witnessed the tragic outcomes of multiple global health crises. From Ebola to high
prices to antibiotic resistance, these events highlight the fundamental constraints of the current biomedical
research and development (R&D) system in responding to patient needs globally.
To mitigate this lack of responsiveness, over 100 self-identified “alternative” R&D initiatives, have emerged in the
past 15 years. To begin to make sense of this panoply of initiatives working to overcome the constraints of the
current system, UAEM began an extensive, though not comprehensive, mapping of the alternative biomedical R&D
landscape. We developed a two phase approach: (1) an investigation, via the RE:Route Mapping, of both existing
and proposed initiatives that claim to offer an alternative approach to R&D, and (2) evaluation of those initiatives to
determine which are in fact achieving increased access to and innovation in medicines. Through phase 1, the RE:
Route Mapping, we examined 81 initiatives that claim to redress the inequity perpetuated by the current system via
one of five commonly recognized mechanisms necessary for truly alternative R&D.
Preliminary analysis of phase 1 provides the following conclusions:
1. No initiative presents a completely alternative model of biomedical R&D.
2. The majority of initiatives focus on developing incentives for drug discovery.
3. The majority of initiatives focus on rare diseases or diseases of the poor and marginalized.
4. There is an increasing emphasis on the use of push, pull, pool, collaboration and open mechanisms alongside
the concept of delinkage in alternative R&D.
5. There is a trend towards public funding and launching of initiatives by the Global South.
Given the RE:Route Mapping’s inevitable limitations and the assumptions made in its methodology, it is not intended
to be the final word on a constantly evolving and complex field; however, its findings are significant. The Mapping’s
value lies in its timely and unique insight into the importance of ongoing efforts to develop a new global framework
for biomedical R&D. As we progress to phase 2, an evaluation tool for initiatives focused on identifying which
approaches have truly achieved increased innovation and access for patients, we aim to demonstrate that there
are a handful of initiatives which represent some, but not all, of the building blocks for a new approach to R&D.
Through this mapping and our forthcoming evaluation, UAEM aims to initiate an evidence-based conversation
around a truly alternative biomedical R&D model that serves people rather than profits.
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Background: a system putting the profits of a few
over the needs of the many
Today the world is witness to the tragic outcomes of the
West African Ebola outbreak, the soaring price of medi-
cines in both rich and poor countries, and the lack of
major new antibiotics to address the spread of microbial
disease. Together these events have further highlighted
the constraints of the current biomedical research and
development (R&D) system, which make it unresponsive
to many of the ever-growing needs of patients globally.
For over two decades, concerns have been raised about
the current biomedical R&D system.1 Since the passage
of international patent protection laws in the mid 1990s
[1], evidence of the multiple ways that people in lower
income settings are deprived of access to affordable and
appropriate medications has grown. The World Health
Organization (WHO) has maintained its estimate made
in 2000 that at least one in three people worldwide lack
access to essential medicines and 10 million people per
year die as a result [2]. In 2009, total global investments
in health R&D amounted to US$240 billion. Yet in 2010,
only about one percent of all health R&D investments
were dedicated to neglected diseases [3]. Furthermore,
under the current system, therapeutic advances are a rarity
with the majority of new drugs showing little to no added
value compared to previously available treatments [4].
Today, this crisis of high prices spans the entire disease
spectrum and affects populations in all countries. From
2014 to 2015 alone, drug prices increased almost 14 % in
the United States (US) [5]. A bipartisan report from the
US Senate Finance Committee showed that Gilead’s “pri-
cing strategy was focused on maximizing revenue” [6].
The result is a price tag of US$84,000 for a 12-week
course of their Hepatitis C treatment Sofosbuvir, brand-
named Sovaldi ® [7]. A recent study showed that manufac-
turing costs for similar drugs are as low as US$21 to
US$63 per 12-week treatment course [8]. A study on the
pricing of four oral cancer drugs found that mass generic
production of the evaluated drugs could result in treat-
ment prices ranging from US$128 to $4020 while current
US prices range from $75,161 to $139,138 [9]. The true
cost of developing a novel drug varies depending on
whom you ask. Industry claims that high prices are
justified in order to recoup the alleged massive invest-
ment required to complete R&D. A widely refuted re-
port from Tufts university claims it costs
approximately $2.6 billion per drug [10, 11]. However,
product development organizations, among others, have
quoted far lower values. The Drugs for Neglected Diseases
Initiative (DNDi), for example, estimates the cost of
drug development to be $110 million [12]. Additionally,
civil society groups and academics have clear analysis dem-
onstrating how drug prices often have little to do with the
actual cost of R&D [13]. As the US Senate Finance Com-
mittee pointed out in its recent investigation, drug prices
have more to do with the price that the market will bear
[14]. This market logic guiding corporate pricing is also
reflected in the pharmaceutical industry’s neglect of many
unprofitable areas of R&D.
We need a people-centered framework for R&D
On the surface, the UAEM Re:Route Mapping shows an
impressive range of alternative biomedical R&D initiatives
challenging the current system by tackling issues that have
long contributed to lack of access to and innovation in
medicines. Furthermore, the implementation of delinkage,
wherein the price of a medicine is not correlated with the
cost of its R&D, by many of the initiatives indicates a step
in a positive direction. Yet, initial observations from the
Mapping point to a lack of fundamental systemic change.
While some initiatives have undoubtedly made important
advances on specific diseases and broader systemic issues,
others are simply promoting a “business as usual” ap-
proach. And despite these manifold initiatives claiming to
fix the system, shockingly little has changed for the major-
ity of people trying to access essential medicines. The
Ebola outbreak epitomizes the pitfalls of the current
piece-by-piece approach. GAVI’s recent commitment to
further develop, license and stockpile an Ebola vaccine
previously owned by Merck & Co Inc. is laudable [15].
However, it comes too late for many. The West African
Ebola outbreak has claimed over 11,000 lives [16] while
GlaxoSmithKline and the National Institutes for Health
left the vaccine sitting on the shelf for years due to lack of
potential profits from its further development [17]. If a
system that worked to meet the needs of all populations
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had been in place, a vaccine for Ebola, and now for Zika
virus, would already exist and be on the market before
these diseases became a global threat [18].
The Mapping supports ongoing calls for a new approach
to R&D. Over the past decade, various actors and policy
processes have acknowledged the need for a new approach
to medical innovation. One key proposal is to create a glo-
bal agreement or framework for biomedical R&D.1 The
need for new global approaches was reinforced by United
Nations (UN) Secretary-General Ban ki-Moon when he
called for a new deal on access to medicines during the
establishment of the High-Level Panel for Access to
Medicines in 2015 [19]. The Mapping reveals a frag-
mented and haphazard landscape that will not lead to a
truly new approach to biomedical R&D. One reason is
that many initiatives are based on the notion that the
current biomedical R&D system needs to be fixed and
some of its side effects remedied. Yet, the current sys-
tem is not broken. It was designed to treat health as a
commodity and it is successfully maintaining that ap-
proach. The myriads of short and long-term fixes cur-
rently being debated are important steps in the process
but will not change the fundamental nature of that
profit-driven system [20]. In our view, while incremen-
tal steps are important and necessary, it is past time to
directly address the underlying constraints inherent in
the current R&D system.
Mapping alternatives: methodology, limitations &
preliminary observations
Methodology
A large and growing number of self-identified “alternative”
R&D initiatives have emerged in the past fifteen years [20].
In light of the 2005 WHO Commission on Intellectual
Property Rights, Innovation and Public Health (CIPIH)
Report, the WHO Consultative Expert Working Group
on Research and Development: Coordination and Finan-
cing (CEWG) actively called for projects to demonstrate
alternative ways of approaching biomedical R&D and since
then the alternative landscape has continued to evolve [21].
In order to understand which of the multiple initiatives
truly respond to the ongoing call for alternatives, Univer-
sities Allied For Essential Medicines (UAEM) carried out
an extensive, though not exhaustive, two phase mapping
of the alternative biomedical R&D landscape. Phase 1
mapped the initiatives, existing or proposed, that claim
to be an alternative approach to biomedical R&D.
Phase 2, not yet published, will evaluate which of those
existing and proposed initiatives are already achieving in-
creased access to and innovation in medicines.
The Re:Route Mapping represents phase 1 of this ef-
fort. We reviewed more than 130 “alternative” initiatives
using a simple methodology based on a specific set of
defined inclusion and exclusion criteria. These were
developed from accepted alternative mechanisms [22]
such as delinkage of prices from costs of R&D, open-
ness, collaboration and use of push, pull, and/or pool-
ing (Refer to Criteria). We retained 81 initiatives that
aim to redress the shortcomings of the current biomed-
ical R&D system and that fulfilled at least one of the in-
clusion criteria. We then separated the initiatives into
existing initiatives (49), which are currently underway,
and proposed initiatives (32), which are not yet in place
but show signs of ongoing development. We categorized
the initiatives by first separating them according to the
stage of the biomedical R&D system they primarily seek to
address, and second identifying the key innovation and ac-
cess principles they apply. This allowed us to identify types
of initiatives through mode of action within the R&D
process and then to further differentiate each initiative in
terms of alternative mechanisms to financing and/or com-
pleting R&D that are regularly implemented.
Criteria: alternative mechanisms for biomedical
R&D [23]
 Push Mechanism: Direct funding for R&D, often in
the form of a grant, as well as indirect incentives,
such as tax breaks and in-kind contributions, which
help finance R&D upfront and thus mitigate the
R&D investment required.
 Pull Mechanism: Mechanisms to incentivize R&D
activities through the promise of financial rewards
once specified objectives or milestones have been
met, creating viable market demand.
 Pooling Mechanism: Pooling of funds that are
aggregated and managed jointly by an established
entity to be allocated based on priority setting in
order to distribute risk and finance biomedical R&D.
Additionally, pooling of intellectual property (IP),
typically via a patent pool, an agreement between
two or more patent owners to pool their patent
rights and license the rights to use these patents
together to one another as well as third parties.
These two distinct types of pooling can occur
independently or jointly.
 Collaborative Initiative: Involves a network,
consortium, or partnership between two or more of
any academic or research institutions, non-profit
organizations, non-governmental organizations
(NGOs), governments, government entities, or
members of the private sector including biotech
and pharmaceutical companies and is often used to
facilitate knowledge sharing.
 Open Initiative: Applies open source, open access,
open data, or open knowledge principles. Interested
parties are able to contribute knowledge or know-how,
data, technology, etc. to be shared in the public domain
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and, in the case of open source, in coordination with
patent-free research.
Limitations
We recognize that the Mapping methodology has limita-
tions and that there are gaps. From the outset, our ap-
proach was driven by the pressing need to develop a
consolidated “snapshot” of the current alternative R&D
landscape, especially given the various high level inter-
national processes undertaken to better understand and
address the constraints of the current system [24] This
project was not meant to result in a comprehensive and
objective scientific study of alternative approaches.
Given the rapidly developing context and the lack of
clarity around what is or is not alternative, we were
forced to make assumptions. However, several experts
reviewed our methodology and, while there are poten-
tially other ways to categorize alternative biomedical
R&D initiatives, together we agreed that separating ini-
tiatives by phase of the pipeline was the least subjective
of the typologies considered.
There is currently no existing basis for categorization
of these initiatives so we had to determine what method-
ology was most appropriate as well as apply it using peer
review and consensus building. We accept that some ini-
tiatives could be classified differently. Similarly, some
overlap and blurring between categories and approaches
is inevitable. We used our best judgment based on the
information publicly available to us. We provide an ex-
tensive glossary in the Mapping to explain our approach
and assumptions. In the spirit of openness and collabor-
ation, we are open to feedback and critique.
As set out in the important user notes of the Mapping,
this Report does not aim to make any judgments on the
value of different areas of drug development or individ-
ual initiatives and their work. Rather, it highlights areas
where alternative approaches are currently more commonly
applied. The report draws attention to what is already out
there and provides a starting point for an ongoing and
inclusive dialogue informed by facts. It presents reliable
and significant preliminary findings, summarized below,
and indicates that more research needs to be done in
order to better understand how to unify and coordinate ef-
forts towards needs-driven R&D.
Preliminary observations
Firstly, none of the initiatives included in the Mapping
present a completely alternative model of biomedical
R&D or a new system (Fig. 1). Having classified the ini-
tiatives according to elements of the biomedical R&D
process, we see the majority of the initiatives address just
one aspect of the biomedical R&D chain, a few try to
address multiple parts of the pipeline and very few seek
to apply a revolutionary or novel approach to biomed-
ical R&D.
Among the 49 existing R&D-related initiatives, we did
not find an initiative that both addressed four or more
of the five key innovative R&D mechanisms we identified
(push, pull, pool, collaborative and open) and utilized the
concept of delinkage. Of the 32 proposed initiatives
however, we found six (19 %) that covered four or more
key mechanisms and embraced the concept of delinkage.
Disappointingly, these six initiatives remain un(der)funded
and/or without active projects.
Second, the initiatives are largely focused on rare
diseases or diseases of the poor and marginalized.
Nearly 9 in 10 of the existing initiatives focus on neglected
tropical diseases (NTDs), rare diseases or malaria,
Fig. 1 Preliminary Findings. The figure shows the breakdown of included initiatives based on whether they implemented one or more of the
defined alternative mechanisms as well as based on source of funding and geographical origin
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Tuberculosis (TB) and/or HIV, while 40 % (19) of the pro-
posed initiatives focus on NTDs and rare diseases.
While NTDs represent real needs, the fact that only 3
existing initiatives and 1 proposed initiative focus on
chronic and non-communicable diseases (NCDs) high-
lights a lack of attention to an important and distinct por-
tion of global health needs [25]. New antibiotic
development is a key focus of only 2 % of existing but
16 % of proposed initiatives, all of which are based in the
North and publicly funded. It is also striking to note that
only 4 % (2) of the existing initiatives and 32 % (7) of the
proposed initiatives focus on diagnostics, a critical stage of
medical treatment.
Third, there is an increasing emphasis on the use of
push, pull, pool, collaboration and open mechanisms
alongside the concept of delinkage in alternative R&D
(Fig. 1). The number of initiatives implementing push
mechanisms has increased from 14 % existing (7) to 50 %
proposed (16), the number of initiatives with pooling has
risen from 2 % existing (1) to 47 % proposed (15) and
openness is an overt strategy in 10 % of existing (5) com-
pared to 32 % of proposed (10) initiatives. Pull mecha-
nisms have become slightly more prevalent, present in
16 % of existing (8) and 25 % of proposed (8) initiatives,
whereas collaboration has remained fairly constant, present
in 24 % of existing (12) and 28 % of proposed (9) initiatives.
Additionally, implementation of more than two mecha-
nisms is prevalent in both existing (32.5 %) and proposed
(56 %) initiatives. While only one existing initiative applies
three mechanisms together, 8 proposed initiatives apply
three or more mechanisms, indicating an increase in joint
application of alternative mechanisms.
Finally, we observed that there is a trend towards
public funding and launching of initiatives by the Glo-
bal South (Fig. 1). Only 20 % of existing (10) initiatives
rely solely on public funding sources, compared to 50 % of
proposed (16) initiatives. As demand for public funding
has grown, reliance solely on private funding sources has
dropped from 29 % existing to 12 % proposed. Reliance on
public and private funding sources together has also de-
clined from 51 % existing to 38 % proposed. While,
78 % of existing and 69 % of proposed initiatives origi-
nated in the North, there seems to be a slight trend to-
wards more initiatives being developed in the South.
Next steps
In light of these findings, UAEM is now launching the sec-
ond phase of the mapping process, the development of an
evaluation tool for initiatives, focused on identifying which
practices or approaches have achieved increased pharma-
ceutical innovation and access to medicines for patients.
Further analysis on aspects of included initiatives such as
funding, intellectual property, and pricing will be con-
ducted after we have collected additional data to xmake
our evaluation as robust and informative as possible.
UAEM believes that through collaborative, criteria-based
and in-depth evaluation, the practices applied and princi-
ples followed by promising initiatives can serve as building
blocks for an overarching framework to govern and guide
R&D. This tool will be available online and will evaluate
and score all 81 initiatives in key metrics relating to ac-
cess, innovation, and collaboration. It will be modeled
after UAEM’s Report Card project, making it feasible to
directly compare initiatives and provide key evidence con-
cerning best practices as well as where improvement re-
mains needed in alternative R&D. Publicly sharing this
information through an online evaluation tool will foster
renewed and ongoing dialogue concerning the criteria and
principles to be laid out for a framework for biomedical
R&D that is patient-oriented and needs-driven.
Conclusion
While we are morally bound to do what we can today to
improve patient access to medicines, we must also be
bold enough to collectively aim for and work towards a
novel, ethical and rights-based way of carrying out bio-
medical R&D that can benefit all those who need access
to lifesaving medicines. Through this mapping and through
the evaluation of existing and proposed alternative R&D
initiatives, UAEM aims to initiate an evidence-based con-
versation around a truly alternative biomedical R&D model
that serves people rather than profits.
To view UAEM’s Re:Route Mapping, please visit
www.altreroute.com
Endnotes
1Actors and stakeholders recommending new global
rules for R&D include: (1) The United Nations Secretary-
General’s High-Level Panel (UNHLP, 2015) on Access to
Medicines, info available at http://www.unsgaccessmed-
s.org/, (2) Suerie Moon, Jorge Bermudez, and Ellen’t Hoen.
“Innovation and access to medicines for neglected popula-
tions: could a treaty address a broken pharmaceutical R&D
system?” PLoS medicine 9.5 (2012): 522., (3) Health Action
International Global, Initiative for Health and Equity in
Society, Knowledge Ecology International, Medecins Sans
Frontieres,Third World Network (2011) An essential health
& biomedical treaty. Available at http://www.who.int/phi/
news/phi_1_joint_submission_en.pdf., (4) WHO Consulta-
tive Expert Working Group on Research and Development:
Financing and Coordination (CEWG, 2009) & Demonstra-
tion Projects, info available at http://www.who.int/phi/
cewg/en/, (5) Governments of Bangladesh, Barbados,
Bolivia, and Suriname (2009) Proposal for WHO discus-
sions on a biomedical R&D treaty. Available at http://
www.who.int/phi/Bangladesh_Barbados_Bolivia_Suriname_
R_DTreaty.pdf (6) Intergovernmental Working Group
(IGWG, 2006) on Public Health, Innovation and
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Intellectual Property & Global Strategy and Plan of Ac-
tion (GSPoA, 2008) for Public Health Innovation and
Intellectual Property. Available at http://www.who.int/
phi/igwg/en/, (7) Dentico N, Ford N (2005) The cour-
age to change the rules: A proposal for an essential
health R&D treaty. PLoS Med 2(2): e14. doi:10.1371/
journal.pmed.0020014., (8) Hubbard T, Love J (2004) A
new trade framework for global healthcare R&D. PLoS
Biol 2(2): e52. doi:10.1371/journal.pbio.0020052., and
(9) WHO Commission on Intellectual Property Rights,
Innovation and Public Health (CIPIH, 2003). Available
at http://www.who.int/intellectualproperty/en/
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